Can You Take Wegovy and Mounjaro at the Same Time?

What the trial data says, and why it only covers one drug at a time

Every licensed clinical trial for these medicines tested a single active treatment against placebo, not against another GLP-1 or dual agonist running alongside it. SURMOUNT-1, published in the New England Journal of Medicine, showed tirzepatide (Mounjaro) produced an average body-weight reduction of around 20–21% at the 15 mg dose over 72 weeks. The STEP 1 trial, also in the NEJM, reported roughly 15% average weight loss with semaglutide 2.4 mg (Wegovy) over 68 weeks. Those figures are for monotherapy, one drug, one carefully managed titration schedule, one set of side-effect data.

No regulatory body, including the MHRA, has evaluated or authorised these medicines as a combined regimen. The licensed indication for each covers adults prescribed that medicine alone. Prescribing both simultaneously would sit entirely outside the evidence and outside the licence, which is why no reputable prescriber does it.

The more useful comparison question is head-to-head performance. The SURMOUNT-5 trial, referenced in NICE's appraisal of tirzepatide (TA1026), pitted tirzepatide directly against semaglutide 2.4 mg over 72 weeks in adults with obesity and no diabetes. Tirzepatide produced greater average weight reduction. That gap narrows somewhat with the newer Wegovy 7.2 mg dose, approved by the MHRA in early 2026, which reported around 20.7% average weight loss in trials. These are the numbers to use when comparing, not a hypothetical combination.

How the two medicines differ, and why combining them does not simply add up

Mounjaro activates two receptors (GIP and GLP-1) making it the only dual agonist licensed for weight management in the UK. Wegovy activates the GLP-1 receptor alone. On paper, adding a pure GLP-1 agonist on top of a dual agonist might seem to intensify the GLP-1 effect, but human physiology does not work like a dosage sum. Both medicines slow gastric emptying, reduce appetite and affect insulin secretion through similar downstream mechanisms. If you are wondering whether you can use Ozempic and Mounjaro at the same time, the answer is that piling them together would compound side-effect risk (severe nausea, vomiting, dehydration and the pancreatitis risk flagged in the MHRA's January 2026 Drug Safety Update) without any evidence of additional benefit.

The NHS medicines page for tirzepatide and the equivalent for semaglutide both note that patients should tell their prescriber about all medicines they are taking, precisely because interactions and overlapping mechanisms matter. A prescriber who saw both on your medicines list would not continue both.

For a clean side-by-side of how these two medicines compare on their own terms, the Wegovy versus Mounjaro comparison page covers the key differences in mechanism, trial results and eligibility in detail.

Switching between them, and what the comparison table tells you

The clinically appropriate alternative to taking both at once is switching from one to the other under prescriber supervision. That process has its own considerations, covered separately at switching from Wegovy to Mounjaro. Briefly: there is no licensed cross-titration schedule, so the timing and starting dose on the new medicine is a prescriber decision based on your current dose, your response and any side effects.

If the comparison between the two medicines as standalone treatments is what you are really after, this detailed breakdown goes further on eligibility thresholds, cost context and how the clinical decision is made. Questions about whether you can take Ozempic and Mounjaro in the same week are addressed at /pages/can-you-take-semaglutide-and-tirzepatide-at-the-same-time.

Which of these medicines suits you is a clinical decision our prescribers make with you, based on your health history, BMI, other medications and your goals. Speak to our prescribers through a free consultation and get a same-day clinical review.